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Abstract
Background: Genome-wide association studies have identified susceptibility genes for development of type 2 diabetes. We
aimed to examine whether a subset of these (comprising FTO, IDE, KCNJ11, PPARG and TCF7L2) were transcriptionally
restricted to or enriched in human beta cells by sorting islet cells into alpha and beta – specific fractions. We also aimed to
correlate expression of these transcripts in both alpha and beta cell types with phenotypic traits of the islet donors and to
compare diabetic and non-diabetic cells.
Methodology/Principal Findings: Islet cells were sorted using a previously published method and RNA was extracted,
reverse transcribed and used as the template for quantitative PCR. Sorted cells were also analysed for insulin and glucagon
immunostaining and insulin secretion from the beta cells as well as insulin, glucagon and GLP-1 content. All five genes were
expressed in both alpha and beta cells, with significant enrichment of KCNJ11 in the beta cells and of TCF7L2 in the alpha
cells. The ratio of KCNJ11 in beta to alpha cells was negatively correlated with BMI, while KCNJ11 expression in alpha cells
was negatively correlated with age but not associated with BMI. Beta cell expression of glucagon, TCF7L2 and IDE was
increased in cells from islets that had spent more time in culture prior to cell sorting. In beta cells, KCNJ11, FTO and insulin
were positively correlated with each other. Diabetic alpha and beta cells had decreased expression of insulin, glucagon and
FTO.
Conclusions/Significance: This study has identified novel patterns of expression of type 2 diabetes susceptibility genes
within sorted islet cells and suggested interactions of gene expression with age or BMI of the islet donors. However,
expression of these genes in islets is less associated with BMI than has been found for other tissues.
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Introduction
Type 2 diabetes, with the exception of rare monogenic forms of
the disease [1], arises from interactions between the genetic
background of the patient and their environment. While the
environmental component, for example the impact of obesity, has
been well studied [2], examining the impact of genetic background
on this disease has been more difficult. The most powerful studies
in this field have been genome-wide association studies seeking to
correlate single nucleotide polymorphisms (SNPs) with incidence
of diabetes in very large sample sizes [3,4,5]. These studies have
uncovered or confirmed several candidates for genetic determi-
nants of type 2 diabetes susceptibility. Subsequent to these
findings, other studies have sought to associate either SNPs in
these genes, or expression of their RNA, with phenotypic
characteristics of tissue donors. However, these have often focused
on peripheral tissues such as adipose tissue, liver and muscle.
Despite the importance of beta cell function to the development of
diabetes, less attention has been given to the expression of these
genes in human pancreatic islets (with the exceptions of KCNJ11
and TCF7L2) due to the lesser availability of this tissue. In the
present study we examined expression of FTO, IDE, KCNJ11,
PPARG and TCF7L2 in sorted human islet cells. These genes were
among the first type 2 diabetes susceptibility genes to be identified
and are some of the most well characterised with regard to their
function (although it should be noted that the association is
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to functional differences in the gene, and for IDE it is as yet
unclear if the risk SNP is located in the IDE or the adjacent
HHEX locus). In the case of KCNJ11 and TCF7L2 we wished to
investigate the relative distribution of these transcripts between
alpha and beta cells, while for FTO, PPARG and IDE we aimed to
find whether these genes are transcribed in islet cells at all. In all
cases, we were interested to see whether expression correlated with
age or BMI. We also examined insulin and glucagon mRNA
expression, as positive controls for each cell type.
In peripheral tissue, correlations have been observed between
the BMI of the tissue donors and mRNA expression of type 2
diabetes susceptibility genes including FTO, PPARG and TCF7L2
[6,7,8,9,10,11]. Interestingly, high levels of FTO mRNA were not
only associated with obesity but also with high levels of mRNA
expression of the adipokines leptin, perilipin and visfatin [11]. In
islets, TCF7L2 has been extensively studied, but generally by
analyzing the effect of SNPs on islet function, donor phenotype or
probability of developing diabetes. Studies manipulating TCF7L2
expression in islets have yielded mixed results, with some showing
that increasing TCF7L2 decreases glucose-induced insulin secre-
tion and islet viability [12], while others show the opposite [13,14].
Interestingly, Lyssenko and colleagues showed that there was a
positive correlation between insulin mRNA and TCF7L2 mRNA
in human islets, although increasing TCF7L2 mRNA also
correlated negatively with glucose-stimulated insulin secretion
[12]. However, recent work has suggested that TCF7L2 mRNA
and protein are oppositely regulated [15], so interpretation of
results only examining TCF7L2 mRNA should be treated with
caution. Moreover, several splice variants of TCF7L2 mRNA have
been identified, with differing patterns of tissue-specific expression
including one variant that is unique to pancreatic islets [16].
KCNJ11 has been known to be a component of the ATP-sensitive
potassium channel for many years, with clear implications for both
insulin and glucagon secretion. Heterozygous activating point
mutations in the protein have been identified in cases of
permanent neonatal diabetes [17], in addition to the SNPs
associated with mildly increased risk of type 2 diabetes [18,19,20].
However, its expression patterns within the human islet are not
known, although it has been shown to be enriched in alpha cells in
rat islets [21]. Less is known about the function of IDE in islets,
although studies in the INS cell line have shown that it is capable
of degrading amylin as well as insulin, and that its amylin-
degrading function may be important for the function of the beta
cell by keeping it clear of amyloid-like aggregates [22,23]. An IDE
knockout mouse exhibited hyperinsulinism and glucose intoler-
ance, thought to be due to insufficient insulin clearance by the liver
[24].
In this study we sorted human islet cells into beta and alpha
fractions using a FACS-based method [25]. This has previously
been used for investigating mRNA expression in purified beta cells
[26]. It also possesses the advantage of providing both alpha and
beta cell types, and with higher yield than can be obtained with
laser capture microdissection [27]. Since type 2 diabetes is a
bihormonal disease with dysregulation of alpha cell as well as beta
cell function, this method is especially valuable since each cell type
can be analysed in isolation. We hypothesised that genes which are
known to be expressed in islets and which confer susceptibility to
type 2 diabetes could display enrichment in the beta cells, or
correlate with phenotypic characteristics of the islet donors, as has
been found in other tissues [6,7,8,9,10,11]. We therefore aimed to
examine the expression of the selected type 2 diabetes suscepti-
bility genes in both fractions and search for correlations between
gene expression in either fraction, or the ratio of expression
between the alpha and beta cells, with the age and BMI of the islet
donors. In this context, PPARG should act as a negative control
since it is thought to exert its influence on type 2 diabetes
susceptibility through its action in other tissues (adipose tissue and
liver) rather than the islet. Finding such correlations between islet
cell-specific mRNA expression of type 2 diabetes susceptibility
genes and phenotypic characteristics of the islet donors, or
differences in gene expression between diabetic and non-diabetic
islet cells, could therefore shed light on novel mechanisms of
regulation of alpha or beta cell function. This study thus adds to
the body of knowledge on the tissue-specific expression of these
important genes and indicates further experimental directions to
follow with regard to their effect on islet cell function.
Methods
Ethics Statement
Human pancreata were harvested from brain-dead organ
donors after informed consent was obtained in writing from
family members. Each islet isolation centre (University of Pisa,
Geneva University Hospital, Leiden University Medical Centre
and the University Hospital of Lille) had permission to isolate islets
and to use them for scientific research if they are insufficient for
clinical islet transplantation, in accordance with national laws and
institutional ethical requirements. Ethical approval for this project
was given by the Central Institutional Review Board on Clinical
Research of Geneva University Hospital.
Islet and cell culture
Intact human islets and sorted islet cells were cultured in CMRL
1066 medium (5.6 mM glucose) supplemented with 10% FCS,
1 mM Hepes, 100 U/ml penicillin, 100 mg/ml streptomycin and
100 mg/ml gentamicin at a density of approximately 10,000 IEQ
per 20 ml medium. Islets were maintained in non-adherent
75 cm
2 cell culture flasks (Corning) for at least one day before
beta cell sorting to allow recovery from the stress of the islet
isolation procedure and to expose all islets to uniform culture
conditions. Details of islet donors are given in Table 1.
Beta cell purification
Dissociation of islet cells was achieved by incubation with
constant agitation for 3 minutes at 37uC in 0.05% trypsin-EDTA
(Invitrogen) supplemented with 3 mg/ml DNAse I (Roche)
followed by pipetting vigorously to complete the dissociation.
Labeling and sorting of alpha and beta cell fractions was
performed as described [25] by Newport Green labeling [28]
followed by FACS. Approximately 10,000 IEQ were used per
isolation.
Table 1. Islet donor characteristics.
Diabetes status Sex n Age (years) BMI (kg/m
2)
Non-diabetic Male 8 46.7568.61 26.7964.34
Non-diabetic Female 8 49.88619.87 28.8866.49
Type 2 diabetic Male 3 52.3366.17 28.2761.39
Age and BMI are expressed as mean 6 standard deviation. The SD of the age of
the female islet donors is much larger than that of the male islet donors
because the oldest and youngest islet donors were female; however, this did
not affect the mean age.
doi:10.1371/journal.pone.0011053.t001
Islet Cell Gene Expression
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Sorted cells were spun down onto microscope slides by
Cytospin, followed by fixation with 4% paraformaldehyde and
washing in PBS. Cells were permeabilised in PBS +0.2% Triton
X-100 for 15 minutes followed by blocking in PBS +0.5% BSA
+0.05% Triton X-100 for 30 minutes. Cell spots were incubated
with guinea pig anti-insulin and mouse anti-glucagon primary
antibodies (diluted 1/200 in PBS), washed, and incubated with
anti-guinea pig Alexa Fluor 568 and anti-mouse Alexa Fluor 488
(diluted 1/200 in PBS). Nuclei were stained with DAPI. The cells
were examined by fluorescence microscopy and the percentage of
insulin- and glucagon-positive cells in each fraction was quantified.
Insulin secretion static incubations
This was performed as described [25] with cells seeded at a
density of 209000 cells per well in a 24-well plate, except that cells
were also incubated with 5.6 mM glucose and with 20 mM KCl
(in addition to 2.8 and 22.2 mM glucose). Insulin secretion and
content were determined with an enzyme-linked immunoassay kit
(SPI Bio).
Glucagon and GLP-1 quantification
Acid ethanol extracts from beta cells, in which insulin content
had already been measured, were used for glucagon and GLP-1
measurements. Glucagon was quantified using a
125I-labelled
glucagon radioimmunoassay kit, while GLP-1 was quantified using
an ELISA kit specific for the biologically active 7-36 amide and 7-
37 forms of GLP-1 (both from Millipore). Quantification was by
interpolation from standard curves prepared with known concen-
trations of glucagon or GLP-1, as appropriate. Values for each islet
isolation were calculated from 12 replicates of 209000 cells each,
extracted in 0.3 ml of 5% acetic acid in ethanol at 220uC.
Quantitative RT-PCR
RNA from sorted cells (1009000-5009000) was extracted with
the Qiagen RNEasy Micro kit including an on-column DNAse I
digestion step. RNA was converted to cDNA using SuperScript II
(Invitrogen). Primers were designed using Primer Express software
(Applied Biosystems). Primer sequences are provided in Table 2.
Real time PCR was carried out on an ABI 7000 Sequence
Detection system (Applied Biosystems) with the SYBR Green
reagent using the standard curve method. Standard curve cDNA
was prepared from total RNA of whole islets. Amplifications were
performed in duplicate for all samples, and values normalised to
the housekeeping gene RPS29.
Statistical analysis
Averaged data are displayed as mean 6 SEM unless otherwise
stated for the indicated n number (islet isolations from n donors).
Significance of differences in averaged gene expression data
between cell fractions were calculated by unpaired T test assuming
equal variance. Spearman correlation coefficients, correlation p
values and multivariate ANOVA were calculated using the
program SPSS Statistics 17.0 (SPSS, Chicago, USA). Correlations
were corrected for multiple testing by the Benjamini-Hochberg
false discovery rate (FDR) method [29] with the FDR set at 5%. A
value of p,0.05 after FDR correction was considered significant.
Results
Confirmation of cell fraction purity and function
Sorted alpha and beta cells were applied to microscope slides
and co-immunostained for insulin and glucagon in order to detect
the amount of alpha cells in the beta cell fraction, and vice versa
(Figure 1A and 1B, Table 3). We consistently obtained high purity
(89%) beta cells, but the alpha cell fraction had a higher
proportion of insulin and glucagon double negative cells (75%
glucagon positive, 19% double negative). We found 6.2% insulin
positive cells in the alpha cell fraction and 4.7% glucagon positive
cells in the beta cell fraction, confirming that this sorting method
efficiently separates the cell types. The insulin secretory response
of the beta cells to glucose and potassium was also tested
(Figure 1C). Consistent with previous data [25], we found that
these cells responded to high glucose (22.2 mM) and potassium
chloride (20 mM), although there was some variability between
donors at basal glucose. This suggests that, at least in the six
samples tested for insulin secretion, the beta cells have remained
healthy despite the stress of islet isolation followed by cell sorting.
To try to account for the variability between samples, we tested for
correlations between insulin secretion at low glucose, and age,
BMI or islet culture time. No association between any of these
variables was found, so at present we cannot account for the
source of this variability.
Control gene profiling of sorted islet cell RNA
RNA concentrations were measured from samples of sorted
cells where the exact number of cells was known, in order to
calculate the yield of RNA per cell (Figure 2A). It was found that
the beta cells had almost twice as much RNA per cell as the alpha
cells (4.5860.22 pg/cell in the alpha cells but 8.7760.70 pg/cell
in the beta cells, p,0.01), consistent with their larger size. It
was therefore necessary to confirm that the control gene for
quantitative PCR was not over-represented in beta cells. We
measured transcription of the control gene RPS29 (ribosomal
protein subunit 29) in cDNA prepared from these samples,
quantified it using the standard curve method and divided by the
number of cells from which the RNA was prepared. There was
no significant difference in RPS29 transcript quantity per cell
between the cell fractions (Figure 2B), suggesting that beta cells do
not overproduce this transcript relative to alpha cells. All values for
both cell fractions were within two standard deviations of the
mean, suggesting that there is also no significant difference in
RPS29 transcript quantity per cell between islet donors. This result
Table 2. Quantitative PCR primer sequences.
Gene
NCBI accession
no. of source
59 primer
39 primer
RPS29 NM 001032 GAGCCACCCGCGAAAAT
CCGTGCCGGTTTGAACAG
Insulin BT 007778 GCAGCCTTTGTGAACCAACA
TTCCCCGCACACTAGGTAGAGA
Glucagon NM 002054 CAGGCAGACCCACTCAGTGA
CTGGTGAATGTGCCCTGTGA
FTO NM 001080432 GTTCACGGCCTGCACTCAT
CCCTGGCTGCTTTGCTTAAT
IDE NM 004969 CTCGGAACCTTGCTTCAACAC
GGCCCGCTGAAGACGAT
KCNJ11 NM 000525 TTGGCAACACCGTCAAAGTG
GAGGCGAGGGTCAGAGCTT
PPARG NM 138712 GGCTTCATGACAAGGGAGTTTC
AAACTCAAACTTGGGCTCCATAAA
TCF7L2 NM 001146274 CAGATGAAATGGCCACTGCTT
GCATCCTTGAGGGCTTGTCTA
doi:10.1371/journal.pone.0011053.t002
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quantitative PCR in this context and that it will not introduce
bias when comparing relative amounts of other transcripts
between the alpha and beta cells. Having established that we had
an appropriate control gene, we measured insulin and glucagon
transcript levels normalised to RPS29 in both cell fractions from
all non-diabetic donors (Figure 2C). As expected from the
immunofluorescence experiments, high levels of insulin were seen
in the beta cell fraction and glucagon in the alpha cell fraction.
Insulin transcript in the alpha cells was low, as expected, but
despite the small number of alpha cells seen in the beta cell
fraction, glucagon transcript in the beta cells was unexpectedly
high. There was no significant difference observed between male
and female donors for either gene in either fraction (alpha cell
glucagon had a tendency to be higher in RNA from male donors,
but this did not achieve significance, p=0.06).
Insulin, glucagon and GLP-1 content measurement
Following our finding that glucagon mRNA was apparently
highly expressed in the beta cells (Figure 2C) and in light of the
discovery of GIP production in alpha cells by Fujita et al [30] we
tested extracts of beta cells for insulin, glucagon and GLP-1
content. For the six sample sets in which insulin secretion and
content had already been determined, we measured glucagon and
GLP-1 content and compared these to the insulin content
measurements (Figure 2D). The average concentrations of insulin,
glucagon and GLP-1 were 39.9610
3 pg/ml, 1029 pg/ml and
31 pg/ml, respectively. Converted to molar concentrations, these
values correspond to 7000 pM insulin, 294 pM glucagon and
9 pM GLP-1. The molar concentration of glucagon is therefore
4.2% of the molar concentration of insulin (p,0.05) in these
samples, in striking agreement with the 4.73% average contam-
ination of alpha cells in the beta cell fraction (Table 3). Our
rationale for measuring GLP-1 was that beta cells express the
prohormone convertase PC1/3, which is capable of cleaving
preproglucagon peptide to generate GLP-1 [31]. However, GLP-1
content was at the limit of detection of the assay and at only 0.14%
of the molar concentration of insulin in these beta cell extracts
(p,0.05), showing that the beta cells are not synthesising this
peptide either. We therefore conclude that the glucagon content is
due to the cross contamination by alpha cells, but that human beta
cells are capable of glucagon mRNA transcription.
Type 2 diabetes susceptibility gene profiling of sorted
islet cell RNA
We selected the genes FTO, IDE, KCNJ11, PPARG and TCF7L2
as candidates to test for expression in the sorted islet cells.
Transcript levels of these genes were measured in both cell
fractions from all non-diabetic donors and normalised to RPS29.
The ratio of expression (beta cells/alpha cells) was also calculated.
All transcripts were observed in both alpha and beta cell fractions,
and for FTO, IDE and PPARG there was no difference in the
abundance of the transcripts between the alpha and beta cells.
However, KCNJ11 mRNA was enriched in the beta cells, while
TCF7L2 mRNA was enriched (although to a lesser extent) in the
Figure 1. Characterization of alpha and beta cell fractions. A:
Representative image of the beta cell fraction stained for insulin (red) and
glucagon (green). B: Representative image of the alpha cell fraction stained
likewise. C: Insulin secretion from sorted beta cells. Data are displayed as
mean + SEM (islets from separate donors, n=6 for all glucose concentra-
tions and 5 for KCl). Statistical significance was assessed by one-tailed
paired Student’s T test comparing stimulated to basal secretion each time.
doi:10.1371/journal.pone.0011053.g001
Table 3. Quantification of insulin and glucagon positive cells.
Cell fraction Alpha Beta
Insulin positive (%) 6.2065.12 88.5568.76
Glucagon positive (%) 74.47611.12 4.7363.31
Double negative (%) 19.3366.63 6.7366.34
Data are expressed as mean 6 standard deviation of four independent
experiments, with at least 800 cells counted per cell fraction for each one.
doi:10.1371/journal.pone.0011053.t003
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analysed for sex-specific differences in the amounts of transcripts
present in both cell fractions, as for insulin and glucagon, and the
only difference observed was for IDE which was more abundant in
male than in female cells for both cell types (Figure 3B and C,
p,0.01 for the alpha cells and p,0.05 for the beta cells).
Correlation of insulin gene expression with age
Multivariate ANOVA was performed to test for any interaction
effects between age, BMI and sex of the islet donors on gene
expression, in both cell types and on the ratio of expression in beta
to alpha cells. No interaction effects were observed in two-way (age
vs. BMI, BMI vs. sex and age vs. sex) or three-way (age vs. BMI vs.
sex) comparisons. We also confirmed that average age and BMI of
the islet donors was not significantly different between the sexes
(Table 1) and that they did not correlate with each other
(r=20.195, p=0.468). Having established that each of these
variables could be considered separately, we calculated Spearman
non-parametric correlation coefficients for correlations between
insulin and glucagon mRNA expression and age or BMI of the
islet donors, in both cell types. No association was observed
between glucagon (in alpha or beta cells) and age or BMI. In the
beta cells there was a slight negative association of insulin mRNA
with donor age, although this did not reach significance after
multiple testing correction (p=0.056 after FDR).
Correlations of type 2 diabetes susceptibility gene
expression with age or BMI
We calculated correlation coefficients for FTO, IDE, KCNJ11,
PPARG and TCF7L2 mRNA expression with age or BMI in both
cell types and for the ratio of expression in beta to alpha cells, for
all samples together. No significant correlations with age or BMI
were observed for IDE, PPARG or TCF7L2. However, the ratio of
KCNJ11 expression in beta to alpha cells for each donor was
negatively correlated with BMI, suggesting that the enrichment of
KCNJ11 in the beta cells relative to the alpha cells is more
pronounced in donors with low BMI and decreased in donors with
high BMI (Figure 4A). No other correlation of gene expression
with BMI was observed. We observed that FTO expression in beta
cells had a slight negative correlation with donor age (although not
quite at the level of significance after multiple testing correction,
p=0.067 after FDR), but no association with BMI. In the alpha
cells, we also observed a negative correlation of KCNJ11 transcript
with age (Figure 4B). We calculated pairwise correlation
coefficients for all the transcripts against each other, which
revealed that in beta cells insulin, KCNJ11 and FTO correlated
positively with each other (Figure 5A, B and C). There was also a
positive association between KCNJ11 and glucagon in the alpha
cells (Figure 5D), and between TCF7L2 and IDE in both cell types
(Figure 5E, alpha, and F, beta).
Figure 2. Control gene expression in sorted islet cells. A: RNA
yield (picograms per cell) from the sorted islet cell fractions, expressed
as mean + SEM (n=4). B: Housekeeping gene RPS29 transcript quantity
per cell, mean + SEM of quantitative RT-PCR measurements normalised
to cell number (n=6). C: Insulin and glucagon mRNA expression in both
cell fractions, normalised to RPS29, mean + SEM from all non-diabetic
islet donors (n=16). D: Insulin, glucagon and GLP-1 content of beta cell
fractions expressed in pg/ml (note logarithmic axis), mean + SEM of 6
non-diabetic islet isolations which were also used for insulin secretion
measurements in Figure 1C. Statistical significance of differences in
hormone concentrations was by Student’s T test assuming equal
variance.
doi:10.1371/journal.pone.0011053.g002
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Since the islet preparations had not all spent the same length of
time in culture, we investigated whether the culture time had
affected transcription of any of the genes. Calculation of
correlation coefficients between mRNA expression and number
of days spent in culture showed that there was a positive
association between culture time and expression of both TCF7L2
and IDE in beta cells (Figure 6). In alpha cells, no correlation
between culture time and gene expression was observed. For beta
cell glucagon, although the correlation was not significant
(p=0.096), the two samples which had been cultured for 10 or
11 days prior to cell sorting had higher levels of glucagon
transcript in the beta cells than the remainder of the samples
which had been cultured for 7 days or less (Figure 7A). The high
levels of glucagon in these two samples did not account for the
average beta cell glucagon transcript being higher than the
average alpha cell insulin transcript, as there was still significantly
more beta cell glucagon than alpha cell insulin when the outlier
values were excluded (Figure 7B, p,0.01 with or without the
outliers). This finding suggests that the beta cells could
dedifferentiate during islet culture with concomitant production
of glucagon, although some non-alpha cell glucagon transcript is
already present even in recently isolated islets.
Figure 3. Type 2 diabetes susceptibility gene expression in
sorted islet cells. A: mRNA expression of type 2 diabetes susceptibility
genes in alpha cells (white bars) and beta cells (black bars), expressed as
mean + SEM of all non-diabetic islet donors (n=16). Statistical
significance of pairwise comparisons between alpha and beta cell
expression was by Student’s T test assuming equal variance. B:
Expression of the same data in alpha cells only with male (white bars)
and female (black bars) islet donors considered separately (n=8 each).
C: Expression of the same data in beta cells only with male (white bars)
and female (black bars) islet donors considered separately (n=8 each).
doi:10.1371/journal.pone.0011053.g003
Figure 4. Correlations of type 2 diabetes susceptibility gene
expression with age or BMI. Filled square data points represent non-
diabetic donors, empty squares represent diabetic donors. Trendlines,
Spearman correlation coefficients (rho) and their corresponding p
values are calculated on the basis of the non-diabetic data points only.
A: Correlation of the ratio of enrichment of KCNJ11 mRNA in beta cells
relative to alpha cells with BMI. B: Correlation of alpha cell KCNJ11
mRNA with age.
doi:10.1371/journal.pone.0011053.g004
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cells from diabetic islets
Alpha and beta cells were sorted from three preparations of type
2 diabetic islets and gene expression analysed as for the non-
diabetic donors. Beta cell insulin and alpha cell glucagon were
significantly lower in the diabetic cells than in the non-diabetic
cells (Figure 8A, p,0.05 for beta cell insulin and p,0.001 for
alpha cell glucagon). However, no difference was observed in beta
cell glucagon transcripts between diabetic and non-diabetic cells.
There was a tendency for glucagon to be proportionally higher
relative to insulin in the diabetic beta cells (insulin/glucagon ratio
was 5.5362.41 in non-diabetic beta cells but 0.9460.36 in
diabetic beta cells), but this was not significant due to the variation
in the non-diabetic cells (p=0.078). Expression of the type 2
diabetes susceptibility genes in diabetic cells was similar (in amount
and in KCNJ11 beta cell enrichment) to their expression in non-
Figure 5. Correlations of mRNA levels with each other. Filled square data points represent non-diabetic donors, empty squares represent
diabetic donors. Trendlines, Spearman correlation coefficients (rho) and their corresponding p values are calculated on the basis of the non-diabetic
data points only. A: Correlation of beta cell insulin and FTO. B: Correlation of beta cell KCNJ11 and FTO. C: Correlation of beta cell insulin and KCNJ11.
D: Correlation of alpha cell glucagon and KCNJ11. E: Correlation of alpha cell TCF7L2 and IDE. F: Correlation of beta cell TCF7L2 and IDE.
doi:10.1371/journal.pone.0011053.g005
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FTO mRNA were observed in both alpha and beta cells from
diabetic islets (Figure 8C, p,0.05 for alpha and beta cells, diabetic
versus non-diabetic). The individual values were compared to
those of the non-diabetic donors for each of the correlations
previously established, and they did not noticeably deviate from
the trendlines except for low levels of KCNJ11 in the alpha cells
(Figures 4D and 5D).
Discussion
In this study we have examined expression of type 2 diabetes
susceptibility genes in sorted islet cells in order to identify
expression patterns associated with cell type or with phenotypic
characteristics of the islet donors. We have found that the
potassium channel subunit KCNJ11 is enriched in human beta
cells relative to alpha cells. This was surprising, given our previous
finding that in rat islets this gene is more highly expressed in the
alpha cells [21], and emphasises the importance of not assuming
that rodent models can completely recapitulate the situation in
human tissue. The negative correlation between the beta cell
enrichment of KCNJ11 and the BMI of the islet donors is
suggestive of a link between BMI and islet function. However,
there is no way of determining whether increased BMI is a cause
or consequence of lower KCNJ11 transcription in the beta cells.
For example, it could be that increased fat mass puts more stress
on the beta cell leading to decreased transcription of genes
important for beta cell functionality, or alternatively that lower
levels of KCNJ11 mRNA in the beta cell relative to the alpha cell
may result in changed insulin/glucagon ratio and hyperglycaemia,
leading eventually to increased lipid production by the liver and
enhanced fat deposition in the adipose tissue. Although we cannot
distinguish between these scenarios, this work suggests a novel
connection between the ATP sensitive potassium channel and
obesity.
It was also surprising, given the literature on FTO expression in
other tissue types, that we found no association between expression
of FTO and BMI in islet cells. The mechanism of action of FTO in
vivo is yet to be confirmed, although it has been shown to function
in vitro as a DNA demethylase [32] and a transgenic mouse
carrying a point mutation which decreases demethylase activity of
FTO in vitro is protected from high fat induced weight gain [33].
Expression of FTO, regardless of SNP status, was found to be
increased in adipose tissue from obese individuals relative to those
of normal weight [11]. However, we only observed a slight
association with age. This is in agreement with Grunnet et al, who
Figure 6. Effect of islet culture time on TCF7L2 and IDE mRNA
expression in non-diabetic islets. A: Scatter plot of beta cell TCF7L2
mRNA against islet culture time prior to cell sorting. B: Scatter plot of
beta cell IDE mRNA against islet culture time prior to cell sorting.
doi:10.1371/journal.pone.0011053.g006
Figure 7. Effect of islet culture time on beta cell glucagon
transcript levels. A: Scatter plot of beta cell glucagon mRNA against
islet culture time prior to cell sorting (non-diabetic islets only). B:
Average insulin and glucagon levels in non-diabetic islets excluding
those which were cultured for 10 or 11 days (n=14).
doi:10.1371/journal.pone.0011053.g007
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addition to associations with BMI and sex, depending on tissue
type) in adipose tissue and skeletal muscle [34]. This study also
reported correlations between FTO mRNA expression and the
mRNA expression of various other functional genes, including
SLC2A4 (previously GLUT4), PPARGC1A and various genes
involved in oxidative phosphorylation. This finding has interesting
parallels with the correlation found by Zabena et al between FTO
and adipokine expression in adipose tissue, and our findings that
FTO, KCNJ11 and insulin are positively correlated with each other
in human beta cells. We could envisage that FTO might be a
master regulator of metabolic function in various tissues and that
an age-dependent decline in FTO expression is involved in the
decrease of metabolic function occurring during the aging process.
The association between TCF7L2 and IDE suggests that TCF7L2
may play a role in control of transcription of IDE. If confirmed,
this would suggest a novel way by which TCF7L2 contributes to
beta cell viability, since IDE contributes to clearance of islet
amyloid as well as insulin [23]. Intriguingly, on examination of the
promoter of the IDE gene (NCBI accession no. NG_013012) we
observed two sites with the sequence TGCAAAG at -756 and
+240 bases relative to the transcription start site of IDE. This
sequence is known to be a TCF binding site, and it is required for
TCF7L2-mediated regulation of cyclin D1 transcription in human
colon cancer cells [35]. A recent study found that PPARG could
induce transcription of IDE in primary neurons [36], but we did
not find any association between IDE and PPARG in our islet cell
investigations. Indeed, we did not observe any difference in
PPARG expression between cell types or between diabetic and
non-diabetic samples, nor any association with phenotypic
characteristics of the islet donors, as expected for a gene which
exerts its major effect in other tissues than the islet. The positive
association between TCF7L2, IDE and islet culture time might
suggest that the beta cells are adopting a more alpha-cell-like state
during islet culture, especially since average alpha cell TCF7L2
mRNA was found to be higher than average beta cell TCF7L2
(Figure 3A). Differences in TCF7L2 mRNA expression have also
been observed between functionally heterogeneous populations of
rat beta cells, with the lower-responding ‘‘immature’’ beta cells
expressing higher levels of TCF7L2 than the higher-responding
‘‘mature’’ population [37].
A surprising finding of this work was that the beta cell fraction
displayed disproportionally high glucagon transcript relative to
glucagon protein. Since the glucagon protein could be attributed
to cross-contamination by alpha cells (4–5%), we conclude that the
glucagon mRNA is produced, but is under post-transcriptional
control, in the beta cells. This result is consistent with the findings
of Katsuta et al [38] who discovered that insulin and glucagon
are co-expressed in a subset of mature mouse beta cells. The
mechanism of post-transcriptional regulation is unclear, but
could involve islet cell-specific microRNAs. In this context, it is
noteworthy that in the miR375 knockout mouse, beta cell mass
was decreased and alpha cell mass increased, and the mice
displayed hyperglucagonaemia [39]. It may be speculated that
miR375 normally suppresses glucagon translation in the beta cell,
which would be consistent with the phenotype of these mice.
While islet culture time did not show a significant correlation with
beta cell glucagon mRNA, it did appear to increase it after 7 days
of islet culture. Increased beta cell glucagon after long periods of
islet culture is in agreement with Russ et al, who found that labeled
adult human beta cells started to express glucagon protein during
dedifferentiation [40]. However, despite the presence of the
glucagon transcript in the beta cells, during examination of the
immunofluorescence images no double (insulin and glucagon)
positive cell was ever observed. This is also in agreement with
Katsuta et al, who found co-transcription of islet hormones in
sorted mouse beta cells, but no colocalisation of immunofluores-
cence staining for the corresponding proteins [38]. It is still
possible that other factors apart from islet culture time (such as
Figure 8. Insulin, glucagon and type 2 diabetes susceptibility
gene expression in diabetic sorted islet cells. A: Differential
expression of beta cell insulin and alpha cell glucagon in non-diabetic
(white bars) compared to diabetic (black bars) islet cells. B: Expression
levels of type 2 diabetes susceptibility gene in diabetic alpha cells
(white bars) and beta cells (black bars). C: Differential expression of FTO
in both cell fractions from non-diabetic (white bars) compared to
diabetic (black bars) islet cells. Statistical comparison of diabetic to non-
diabetic samples was by unpaired T test assuming unequal variance.
n=16 non-diabetic and 3 diabetic samples.
doi:10.1371/journal.pone.0011053.g008
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gene expression in the sorted cells, but in culturing the islets for at
least 24 hours we hoped to normalise the environment of the islets
in order to minimise the effects of such external factors.
Although it was not unexpected to find lower levels of insulin in
the diabetic beta cells, it was surprising to find decreased alpha cell
glucagon, especially since one of the hallmarks of diabetes is
inappropriately increased glucagon secretion [41]. However, we
have only examined mRNA expression, which may not reflect
glucagon secretion or content. The higher proportion of alpha
cells observed in diabetic islets by Deng et al [42] may play a more
important role in inappropriate glucagon release. However, this
study also revealed lower maximal glucagon release during
perifusion of diabetic islets when stimulated with KCl, possibly
reflecting lower islet glucagon content. The decreased amount of
FTO observed in both cell types from the diabetic islets is also
intriguing. In a previous study comparing gene expression in
diabetic islets against normal islets using DNA microarrays, FTO
was not identified as a differentially regulated gene [43]. Further
studies on the function of FTO in islets would be required to
elucidate whether it plays a role in beta cell viability or
dysfunction, and if so, how.
We acknowledge that this study is limited by a small number of
samples, since the starting material can only be obtained from
organ donors as opposed to peripheral tissue biopsies. Diabetic
islets are less numerous and even more sensitive to the stress of the
isolation process than normal islets ([42] and our own observa-
tions), and it is not often that enough diabetic islets can be
obtained to perform the cell sorting procedure on them. In
addition, we cannot account for any effects of SNPs on gene
expression since the organ donors are not genotyped. This may
explain why we were unable to reproduce the correlation between
insulin and TCF7L2 mRNA expression observed by Lyssenko et al
in whole islets [12]. The primers used for TCF7L2 in our study are
located in exon 5, and would therefore have amplified all splice
variants of TCF7L2 mRNA [16], so we would have been unable to
observe isoform-specific correlations. In the case of FTO it has
been reported that there was no association between SNPs and
FTO mRNA expression by both studies which have examined this
parameter [11,34] so our data on FTO should not be affected by
not knowing the donors SNP status. We consider that our analysis
of RNA expression of type 2 diabetes susceptibility genes in sorted
alpha and beta cells has revealed interesting patterns of gene
expression between cell types and between diabetic and non-
diabetic samples, which may underpin future functional studies on
the mechanisms of action of type 2 diabetes susceptibility genes.
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